Oscar Health, Inc. (OSCR) AI Stock Analysis

Oscar Health, Inc. operates as a health insurance provider in the United States, offering Individual & Family, Small Group, and Medicare Advantage plans across various population segments. The company integrates its proprietary +Oscar technology platform to drive engagement among healthcare providers, payor clients, and patients, with tools intended to streamline care management. Headquartered in New York and founded in 2012, the firm was formerly known as Mulberry Health Inc. before rebranding in January 2021. In addition to health coverage, Oscar Health provides reinsurance products to broaden its financial solutions.

Revenue increased from $1.92B in FY2021 to $11.70B in FY2025, representing an 81.8% 5-year CAGR from FY2020 to FY2025. While annual revenue rose 27.5% in FY2025, net income came in at -$443.2M with a net margin of -3.8%, following positive net income of $25.4M in FY2024. Over the trailing twelve months, revenue reached $15.32B, with a profit margin of 3.6% and operating margin of 8.0%. In the latest quarter ended June 30, 2026, quarterly revenue grew 70.4% year-over-year, while quarterly earnings grew 125.6%.

As of June 30, 2026, Oscar Health held $8.56B in cash and short-term investments against total debt of $431.6M, yielding net cash of $8.12B. The company closed the period with a current ratio of 1.08 and a debt-to-equity ratio of 0.21 on shareholders' equity of $2.05B. During FY2025, operating cash flow was $1.09B, free cash flow was $1.06B, and capital expenditures totaled $36.4M. Its share count increased by 58.9% over five years.

Oscar Health trades at a trailing price-to-earnings multiple of 24.7x, roughly in line with the 24.6x median of its US-listed Healthcare peers. Its forward price-to-earnings ratio is 588.2x compared to the peer median of 17.3x, while its price-to-sales ratio of 0.6x sits below the peer median of 4.1x. The stock carries an enterprise value of $5.78B and an EV-to-revenue multiple of 0.4x. Over the past year, OSCR gained 51.6%, outperforming the S&P 500 (SPY) return of 16.8%.

Wall Street coverage includes 3 Buy ratings, 7 Holds, and 1 Sell. The mean price target is $36.40, implying an upside of 14.1% from the last close of $31.89 on October 16, 2026. For the fiscal year ending December 31, 2026, analysts estimate EPS of $1.94 on revenue of $18.73B. For the following fiscal year, 8 analysts project EPS of $2.22 on revenue of $20.78B. The company beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Oscar Health, Inc. (OSCR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: OSCR income statement, OSCR balance sheet, OSCR key metrics, OSCR analyst forecast, OSCR chart. See the OSCR stock overview for the latest quote and news.